Express Scripts (NASDAQ:ESRX):
Propeller Health and Express Scripts Partnership Offers Innovative Digital Respiratory Care to Improve Health for People with Asthma or COPD.
The company is so far trading up from yesterday’s close of 60.05.
Express Scripts Holding Company, launched on July 15, 2011, is a pharmacy benefit management (PBM) company. The Company is involved in providing healthcare management and administration services to its clients, including managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. The Company operates through two segments: PBM and Other Business Operations. The PBM segment includes its integrated PBM operations and specialty pharmacy operations. Its Other Business Operations segment includes its subsidiary, United BioSource Corporation (UBC), and its specialty distribution operations..
The company currently has a P/E ratio of 10.23 and the market cap is 34.01B. In the latest earnings report the EPS was $6.02 with 566.37M shares outstanding.
Investors are feeling more bearish on shares of Express Scripts if you take note of the uptick in short interest. The company recorded a rise in short interest of 1.04% as of October 13, 2017 from the last reporting period. Short interest increased 342,235 over that timeframe. The days to cover decreased to 8.0 and the short interest percentage is 0.06% as of October 13.
Several Wall Street analysts have issued ratings on Express Scripts. On October 26, 2017 Jefferies Group LLC kept a “Buy” rating on the company. On October 25 analysts at Royal Bank Of Canada issued a report on ESRX and giving a rating of “Hold” and establishing a price target of $66.00.
Equity analyst Robert W. Baird raised the price target on October 25 changing the price objective from $57.00 to $59.00 with a “Neutral” recommendation. Equity analyst Mizuho released a research note on ESRX with a rating of “Hold” and a price target of $67.00.
October 9 investment analysts at Raymond James Financial reiterated a “Underperform” rating on the company. On September 19, 2017 Royal Bank Of Canada updated guidance on ESRX with an initial rating of “Sector Perform”.